SCHEMBL4970852

SCHEMBL4970852

Fc1cnc(CCOc2nc(Cl)nc(N3CCOCC3)c2F)c(F)c1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
JAK2 O60674 6/20 0.40
JAK3 P52333 6/20 0.40
KDM4E B2RXH2 3/20 0.38
SMN1; SMN2 Q16637 3/20 0.37
ELOVL1 Q9BW60 2/20 0.35
MAPT P10636 2/20 0.35
MAPK1 P28482 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35
TSHR P16473 1/20 0.34
HSD17B10 Q99714 1/20 0.34
AOC3 Q16853 1/20 0.34
CYP1A2 P05177 1/20 0.33
CYP2D6 P10635 1/20 0.33
CYP2C9 P11712 1/20 0.33
CYP2C19 P33261 1/20 0.33
TDP1 Q9NUW8 1/20 0.33
BCL6 P41182 1/20 0.33
P2RX3 P56373 1/20 0.33
ADORA2A P29274 1/20 0.33
ADORA1 P30542 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4975393 0.85 JAK2 (0.38) JAK2JAK3KDM4ESMN1; SMN2ELOVL1
SCHEMBL4973170 0.82 JAK2 (0.39) JAK2JAK3KDM4EELOVL1TSHR
SCHEMBL4974714 0.78 JAK2 (0.47) JAK2JAK3KDM4ESMN1; SMN2MAPT
SCHEMBL4974705 0.77 JAK2 (0.49) JAK2JAK3KDM4ESMN1; SMN2MAPT
SCHEMBL4970845 0.76 JAK2 (0.64) JAK2JAK3KDM4ESMN1; SMN2MAPT
SCHEMBL4975389 0.71 JAK2 (0.61) JAK2JAK3KDM4ESMN1; SMN2
SCHEMBL4972050 0.71 JAK2 (0.46) JAK2JAK3KDM4ESMN1; SMN2MAPT
SCHEMBL4975403 0.70 JAK2 (0.49) JAK2JAK3KDM4ESMN1; SMN2MAPK1
SCHEMBL4972038 0.70 JAK2 (0.49) JAK2JAK3KDM4ESMN1; SMN2MAPT
SCHEMBL4973163 0.69 JAK2 (0.63) JAK2JAK3KDM4ESMN1; SMN2RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2008132502-A1 PYRAZOLYL-AMINO-SUBSTITUTED PYRIMIDINES AND THEIR USE FOR THE TREATMENT OF CANCER ASTRAZENECA AB (SE) 2008-11-06 WO disclosed